Adicet Bio says prula-cel last patient visit complete; topline data due Sept 2026, ADI-212 IND cleared
Adicet Bio completed the last patient visit for its Phase 1 prula-cel study in SLE, with topline data expected in September 2026. The FDA cleared the IND for ADI-212 in mCRPC, with Phase 1 enrollment starting in 4Q 2026. The company also announced progress on its in vivo CAR-T platform, with the first candidate expected to enter clinical trials in 2H 2027, according to the company.
How this was made
The 30-second read
Why it matters
The completion of patient enrollment and IND clearance are key milestones that de‑risk the programs and may attract partnership interest.
Market read
New data readouts and IND clearance provide fresh catalysts for the stock.
What to watch
Potential competition from other CAR‑T programs and funding requirements for upcoming trials.
Background
Adicet Bio is a clinical‑stage biotech focused on CAR‑T therapies for autoimmune diseases and cancer.
Ticker impact
Adicet Bio completed the last patient visit for its prula-cel Phase 1 SLE study and announced FDA IND clearance for ADI-212 in mCRPC.
Potential short‑term upside as investors price in future data readouts.
First disclosure of trial completion and IND clearance provides fresh, material information for a clinical‑stage biotech.
Market effects
May lift sentiment in the broader autoimmune and oncology biotech sectors.
Limited to U.S. biotech investors; no broader regional effect.
Modest global relevance as data could interest international biotech funds.
Counterpoint
If trial data later disappoint, early optimism could reverse sharply.
Key entities
- companyAdicet Bio
Clinical‑stage biotech developing CAR‑T therapies.
